Doximity Business Seeing 'Renewed Momentum,' Morgan Stanley Says in Upgrade

MT Newswires Live11-15

Doximity's (DOCS) fiscal Q4 revenue estimate indicates room for upward revision as the company is seeing "renewed momentum" in its business, Morgan Stanley said Thursday.

The company's fiscal Q4 revenue is expected to increase 3% year over year.

"Given the consensus view that Q4 estimates are overly conservative, a key question is how much upside could Doximity deliver in that quarter and what growth will look like in FY26," Morgan Stanley said in a note to clients.

The firm expects Doximity's 2024 revenue to increase 14% year over year, which it said was "well above" its 7% growth outlook for digital ad spending in the healthcare professional market.

"Doximity's outgrowth relative to the industry had been narrowing since outsized performance during COVID, although appears to be widening again in 2024," Morgan Stanley said.

Morgan Stanley said it lifted its fiscal 2025 revenue estimates for the company by 4% to $538 million and boosted its fiscal 2026 estimate by 3% to $581 million.

The firm upgraded its rating on the Doximity stock to equal-weight from underweight while raising its price target to $53 from $33.

Price: 52.55, Change: -0.31, Percent Change: -0.60

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment